Response of women with Fabry disease to enzyme replacement therapy: Comparison with men, using data from FOS-the Fabry Outcome Survey

Molecular Genetics and Metabolism

Volumn 103, Issue 3, 2011, Pages 207-214

  Hughes, Derralynn A ^a   Barba Romero, Miguel Ángel ^b   Hollak, Carla E M ^c   Giugliani, Roberto ^d   Deegan, Patrick B ^e  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^e ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Agalsidase alfa; Enzyme replacement therapy; Fabry disease; Fabry Outcome Survey; Female; Lysosomal storage diseases

Indexed keywords

AGALSIDASE ALFA; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ABDOMINAL PAIN; ANGINA PECTORIS; ANHIDROSIS; ARTHROPATHY; ARTICLE; CHRONIC KIDNEY DISEASE; CHRONIC PAIN; CLAUDICATION; CLINICAL FEATURE; COMPARATIVE EFFECTIVENESS; CONDUCTION DEAFNESS; CONSTIPATION; CONTROLLED STUDY; CORNEA DISEASE; DEPRESSION; DIARRHEA; DRUG EFFICACY; DYSPNEA; ENZYME REPLACEMENT; FABRY DISEASE; FATIGUE; FEMALE; FEVER; HEARING IMPAIRMENT; HEART ARRHYTHMIA; HEART FUNCTION; HEART LEFT VENTRICLE MASS; HEART PALPITATION; HUMAN; HYPERHIDROSIS; HYPERTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NAUSEA; PAIN ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; SEX DIFFERENCE; STROKE; TINNITUS; TREATMENT RESPONSE; VERTIGO; VOMITING;

ADOLESCENT; ADULT; ALPHA-GALACTOSIDASE; CHILD; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; FEMALE; HEALTH SURVEYS; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; SEX FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79958060136     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2011.03.022     Document Type: Article

References (39)

1. Meikle P.J., Hopwood J.J., Clague A.E., Carey W.F. Prevalence of lysosomal storage disorders. JAMA 1999, 281:249-254.
2. Poorthuis B.J., Wevers R.A., Kleijer W.J., Groener J.E., de Jong J.G., van Weely S., Niezen-Koning K.E., van Diggelen O.P. The frequency of lysosomal storage diseases in The Netherlands. Hum. Genet. 1999, 105:151-156.
3. Spada M., Pagliardini S., Yasuda M., Tukel T., Thiagarajan G., Sakuraba H., Ponzone A., Desnick R.J. High incidence of later-onset Fabry disease revealed by newborn screening. Am. J. Hum. Genet. 2006, 79:31-40.
4. Hughes D.A. Early therapeutic intervention in females with Fabry disease?. Acta Paediatr. Suppl. 2008, 97:41-47.
5. Mehta A., Ricci R., Widmer U., Dehout F., Garcia de Lorenzo A., Kampmann C., Linhart A., Sunder-Plassmann G., Ries M., Beck M. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur. J. Clin. Invest. 2004, 34:236-242.
6. Monserrat L., Gimeno-Blanes J.R., Marin F., Hermida-Prieto M., Garcia-Honrubia A., Perez I., Fernandez X., de Nicolas R., de la Morena G., Paya E., Yague J., Egido J. Prevalence of Fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 2007, 50:2399-2403.
7. Terryn W., Poppe B., Wuyts B., Claes K., Maes B., Verbeelen D., Vanholder R., De Boeck K., Lameire N., De Paepe A., De Schoenmakere G. Two-tier approach for the detection of alpha-galactosidase A deficiency in a predominantly female haemodialysis population. Nephrol. Dial. Transplant. 2008, 23:294-300.
8. Rolfs A., Bottcher T., Zschiesche M., Morris P., Winchester B., Bauer P., Walter U., Mix E., Lohr M., Harzer K., Strauss U., Pahnke J., Grossmann A., Benecke R. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet 2005, 366:1794-1796.
9. Linthorst G.E., Bouwman M.G., Wijburg F.A., Aerts J.M., Poorthuis B.J., Hollak C.E. Screening for Fabry disease in high risk populations: a systematic review. J. Med. Genet. 2009, 47:217-222.
10. Mehta A., Clarke J.T., Giugliani R., Elliott P., Linhart A., Beck M., Sunder-Plassman G. Natural course of Fabry disease: changing pattern of causes of death in FOS-the Fabry Outcome Survey. J. Med. Genet. 2009, 46:548-552.
11. Waldek S., Patel M.R., Banikazemi M., Lemay R., Lee P. Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet. Med. 2009, 11:790-796.
12. Hughes D.A., Elliott P.M., Shah J., Zuckerman J., Coghlan G., Brookes J., Mehta A.B. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson? Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 2008, 94:153-158.
13. Germain D.P., Waldek S., Banikazemi M., Bushinsky D.A., Charrow J., Desnick R.J., Lee P., Loew T., Vedder A.C., Abichandani R., Wilcox W.R., Guffon N. Sustained, long-term renal stabilization after 54months of agalsidase beta therapy in patients with Fabry disease. J. Am. Soc. Nephrol. 2007, 18:1547-1557.
14. Schiffmann R., Kopp J.B., Austin H.A., Sabnis S., Moore D.F., Weibel T., Balow J.E., Brady R.O. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001, 285:2743-2749.
15. Eng C.M., Banikazemi M., Gordon R.E., Goldman M., Phelps R., Kim L., Gass A., Winston J., Dikman S., Fallon J.T., Brodie S., Stacy C.B., Mehta D., Parsons R., Norton K., O'Callaghan M., Desnick R.J. A phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am. J. Hum. Genet. 2001, 68:711-722.
16. Schiffmann R., Ries M., Timmons M., Flaherty J.T., Brady R.O. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol. Dial. Transplant. 2006, 21:345-354.
17. Hoffmann B., Beck M., Sunder-Plassmann G., Borsini W., Ricci R., Mehta A. Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy-a retrospective analysis from the Fabry Outcome Survey. Clin. J. Pain 2007, 23:535-542.
18. Baehner F., Kampmann C., Whybra C., Miebach E., Wiethoff C.M., Beck M. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study. J. Inherit. Metab. Dis. 2003, 26:617-627.
19. Whybra C., Miebach E., Mengel E., Gal A., Baron K., Beck M., Kampmann C. A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease. Genet. Med. 2009, 11:441-449.
20. Mehta A., Beck M., Elliott P., Giugliani R., Linhart A., Sunder-Plassman G., Schiffmann R., Barbey F., Ries M., Clarke J.T. Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. Lancet 2009, 374:1986-1996.
21. Eng C.M., Germain D.P., Banikazemi M., Warnock D.G., Wanner C., Hopkin R.J., Bultas J., Lee P., Sims K., Brodie S.E., Pastores G.M., Strotmann J.M., Wilcox W.R. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet. Med. 2006, 8:539-548.
22. Devereux R.B., Alonso D.R., Lutas E.M., Gottlieb G.J., Campo E., Sachs I., Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am. J. Cardiol. 1986, 57:450-458.
23. Lang R.M., Bierig M., Devereux R.B., Flachskampf F.A., Foster E., Pellikka P.A., Picard M.H., Roman M.J., Seward J., Shanewise J.S., Solomon S.D., Spencer K.T., Sutton M.S., Stewart W.J. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J. Am. Soc. Echocardiogr. 2005, 18:1440-1463.
24. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis. 2002, 39:S56. National Kidney Foundation (NKF) Kidney Disease Outcome Quality Initiative (K/DOQI) Advisory Board.
25. Peake M., Whiting M. Measurement of serum creatinine-current status and future goals. Clin. Biochem. Rev. 2006, 27:173-184.
26. Tan G., Jensen M.P., Thornby J.I., Shanti B.F. Validation of the Brief Pain Inventory for chronic nonmalignant pain. J. Pain 2004, 5:133-137.
27. Whybra C., Baehner F., Baron K. Measurement of disease severity and progression in Fabry disease. Fabry Disease: Perspectives From 5years of FOS 2006, 315-322. Oxford PharmaGenesis Ltd., Oxford. A. Mehta, M. Beck, G. Sunder-Plassmann (Eds.).
28. Mehta A., Clarke J.T., Giugliani R., Elliott P., Linhart A., Beck M., Sunder-Plassmann G. Natural course of Fabry disease: changing pattern of causes of death in FOS-Fabry Outcome Survey. J. Med. Genet. 2009, 46:548-552.
29. Linhart A., Kampmann C., Zamorano J.L., Sunder-Plassmann G., Beck M., Mehta A., Elliott P.M. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur. Heart J. 2007, 28:1228-1235.
30. Lang R.M., Bierig M., Devereux R.B., Flachskampf F.A., Foster E., Pellikka P.A., Picard M.H., Roman M.J., Seward J., Shanewise J., Solomon S., Spencer K.T., St John Sutton M., Stewart W. Recommendations for chamber quantification. Eur. J. Echocardiogr. 2006, 7:79-108.
31. Mehta A., Beck M., Elliott P., Giugliani R., Linhart A., Sunder-Plassmann G., Schiffmann R., Barbey F., Ries M., Clarke J.T. Department of error. Lancet 2010, 375:200.
32. Kampmann C., Linhart A., Devereux R.B., Schiffmann R. Effect of agalsidase alfa replacement therapy on fabry disease-related hypertrophic cardiomyopathy: a 12- to 36-month, retrospective, blinded echocardiographic pooled analysis. Clin. Ther. 2009, 31:1966-1976.
33. Vedder A.C., Breunig F., Donker-Koopman W.E., Mills K., Young E., Winchester B., Ten Berge I.J., Groener J.E., Aerts J.M., Wanner C., Hollak C.E. Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3. Mol. Genet. Metab. 2008, 94:319-325.
34. Schiffmann R., Warnock D.G., Banikazemi M., Bultas J., Linthorst G.E., Packman S., Sorensen S.A., Wilcox W.R., Desnick R.J. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol. Dial. Transplant. 2009, 24:2102-2111.
35. West M., Nicholls K., Mehta A., Clarke J.T., Steiner R., Beck M., Barshop B.A., Rhead W., Mensah R., Ries M., Schiffmann R. Agalsidase alfa and kidney dysfunction in Fabry disease. J. Am. Soc. Nephrol. 2009, 20:1132-1139.
36. MacDermot K.D., Holmes A., Miners A.H. Anderson Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J. Med. Genet. 2001, 38:769-775.
37. MacDermot K.D., Holmes A., Miners A.H. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J. Med. Genet. 2001, 38:750-760.
38. Deegan P.B., Baehner A.F., Barba Romero M.A., Hughes D.A., Kampmann C., Beck M. Natural history of Fabry disease in females in the Fabry Outcome Survey. J. Med. Genet. 2006, 43:347-352.
39. Hoffmann B., Keshav S. Gastrointestinal symptoms in Fabry disease: everything is possible, including treatment. Acta Paediatr. Suppl. 2007, 96:84-86.